219754-02-6

Basic information

• Product Name: Boceprevir interMediate
• Synonyms: Boceprevir interMediate;(1R,2S,5S)-3-(tert-butoxycarbonyl)-6,6-diMethyl-3-azabicyclo[3.1.0]hexane-2-carboxylic acid;Racemic-(1R,2S,5S)-3-(Tert- Butoxycarbonyl)-6,6-Dimethyl-3- Azabicyclo[3.1.0]Hexane-2- Carboxylic Acid;Racemic-(1R,2S,5S)-3-(Tert-Butoxycarbonyl)-6,6-Dimethyl-3-Azabicyclo[3.1.0]Hexane-2-Carboxylic Acid(WX112069)
• CAS NO: 219754-02-6
• Molecular Formula: C₁₃H₂₁NO₄
• Molecular Weight: 255.31014
• Mol File: 219754-02-6.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 361.8±25.0 °C(Predicted)
• Appearance: /
• Density: 1.179±0.06 g/cm3(Predicted)
• PKA: 4.04±0.40(Predicted)
• CAS DataBase Reference: Boceprevir interMediate(CAS DataBase Reference)
• NIST Chemistry Reference: Boceprevir interMediate(219754-02-6)
• EPA Substance Registry System: Boceprevir interMediate(219754-02-6)

Safety Data

• Hazardous Substances Data: 219754-02-6(Hazardous Substances Data)

Usage

General Description

Boceprevir intermediate, also known as N-[(1R,2S)-2-(4-chlorophenyl)cyclopropyl]-3-phenylpropanamide, is a chemical compound that serves as a key intermediate in the production of the antiviral medication boceprevir. Boceprevir is a protease inhibitor used in the treatment of chronic hepatitis C virus (HCV) infection. The intermediate compound is crucial for the synthesis of boceprevir and is an important building block in the manufacturing process. It undergoes several chemical reactions and modifications to ultimately form boceprevir, which inhibits the replication of the HCV virus and helps to improve liver function in HCV-infected individuals. The production and availability of boceprevir intermediate are essential for the production of the medication and for addressing the global burden of HCV infection.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 911835-76-2 (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylic acid 
• 569679-06-7 3-(tert-butyl) 2-methyl (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2,3-dicarboxylate 
• 394734-84-0 (1R,2S,5S)-(6,6-dimethyl-3-azabicyclo[3.1.0]hex-2-yl)methanol 
• 219753-99-8 (1S,2S,4S,7R)-6-aza-3,3-dimethyl-8-oxa-7-phenyltricyclo<4.3.0.0>nonan-5-one 
• 1026427-11-1 ((1R,2S,5S)-3-Benzyl-6,6-dimethyl-3-aza-bicyclo[3.1.0]hex-2-yl)-methanol 
• 103201-79-2 (3R,7aS)-3-phenyl-tetrahydro-pyrrolo[1,2-c]oxazol-5-one 
• 134107-65-6 (3R,7aS)-3-phenyl-3,7a-dihydro-1H-pyrrolo[1,2-c]oxazol-5-one 
• 219754-00-4 tert-butyl (1R,2S,5S)-2-(hydroxymethyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-3-carboxylate 

Downstream Products

• 569679-06-7 3-(tert-butyl) 2-methyl (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2,3-dicarboxylate 
• 394735-37-6 (1R,2S,5S)-3-((S)-2-tert-butoxycarbonylamino-3,3-dimethylbutyryl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylic acid 
• 394730-60-0 boceprevir 
• 394735-26-3 (1R,2S,5S)-3-((S)-2-tert-Butoxycarbonylamino-3,3-dimethyl-butyryl)-6,6-dimethyl-3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid methyl ester 
• 394735-27-4 methyl (1R,2S,5S)-3-((S)-2-(3-(tert-butyl)-ureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylate 
• 816444-90-3 (1R,2S,5S)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylic acid 
• 394735-24-1 (1R,2S,5S)-3-((S)-2-tert-Butoxycarbonylamino-2-cyclohexyl-acetyl)-6,6-dimethyl-3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid methyl ester 
• 569678-90-6 (1R,2S,5S)-3-((S)-2-tert-Butoxycarbonylamino-2-cyclohexyl-acetyl)-6,6-dimethyl-3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid 
• 394735-28-5 (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-(tert-butyl)ureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicylo[3.1.0]-hexane-2-carboxamide 

Relevant articles and documents

ANTIVIRAL COMPOUNDS FOR THE TREATMENT OF CORONAVIRUS, PICORNAVIRUS AND NOROVIRUS INFECTIONS

Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating coronavirus, Picomavirus and Norovims infections with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

HCV PROTEASE INHIBITORS AND USES THEREOF

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

Design, synthesis and evaluation of poly-L-proline type-II peptide mimics based on the 3-azabicyclo[3.1.0]hexane system

-